دورية أكاديمية
Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
| العنوان: | Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC. |
|---|---|
| المؤلفون: | Ying HQ; Department of Nuclear Medicine, Jiangxi Province Key Laboratory of Laboratory Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China., Liao YC; Biological Resource Center, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, Nanchang 330006, China., Luo YR; Jiangxi Medical College, Nanchang University, Nanchang 330006, China., Xiong G; Department of Information, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China., Huang Y; Jiangxi Medical College, Nanchang University, Nanchang 330006, China., Nie RW; Jiangxi Medical College, Nanchang University, Nanchang 330006, China., Xiong CF; Jiangxi Medical College, Nanchang University, Nanchang 330006, China., Cheng XX; Biological Resource Center, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, Nanchang 330006, China. Electronic address: cxxncu@163.com. |
| المصدر: | Pharmacological research [Pharmacol Res] 2021 Aug; Vol. 170, pp. 105734. Date of Electronic Publication: 2021 Jun 19. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Validation Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8907422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-1186 (Electronic) Linking ISSN: 10436618 NLM ISO Abbreviation: Pharmacol Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oct. 2015- : Amsterdam ; Elsevier Original Publication: London ; San Diego : Academic Press, c1989- |
| مواضيع طبية MeSH: | Decision Support Techniques*, Antineoplastic Agents/*therapeutic use , Biomarkers, Tumor/*immunology , Carcinoma, Non-Small-Cell Lung/*drug therapy , Inflammation/*immunology , Lung Neoplasms/*drug therapy , Protein Kinase Inhibitors/*therapeutic use , Tumor Microenvironment/*immunology, Antineoplastic Agents/adverse effects ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/mortality ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Female ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Male ; Predictive Value of Tests ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Reproducibility of Results ; Risk Assessment ; Risk Factors ; Time Factors |
| مستخلص: | Objective: Cancer elicited inflammation is the main environmental cause leading to carcinogenesis and metastasis of non-small cell lung cancer (NSCLC). Roles of the inflammatory biomarker in predicting the clinical efficacy of tyrosine kinase inhibitor (TKI) and prognosis of naive patients with advanced NSCLC need to be determined, and the best inflammatory predicted biomarker remains unknown. Methods: A total of 178 eligible advanced NSCLC patients (124 and 54 cases within discovery and validation cohorts, respectively) who received first-line EGFR-TKI between July of 2014 and October of 2020 were enrolled in the present study. We detected circulating immune cell counting, albumin (Alb), pre-albumin (pAlb), ALP, AST, LDH, GGT, HDL-c, and fibrinogen (Fib) concentrations, and calculated 22 inflammatory ratios and scores. Logistic regression and Cox proportional hazards models were used to assess the impact of these ratios and scores on objective response and disease control rate (ORR and DCR) as well as progression-free survival (PFS) in these patients. Results: Twenty-five percentage and 24.07% of NSCLC patients were observed objective response to the treatment of first-line EGFR-TKI in discovery and validation cohort, respectively. Univariate and multivariate Cox regression showed that high PLR, NPS, SII, SIS, mSIS, GLR and FPR as well as low PNI were significantly associated with poor PFS in discovery cohort. However, only high SII and FPR were found to be associated with unsatisfactory outcome in validation cohort. Time-dependent areas under ROC of FPR were 0.702 (0.517-0.888) in discovery cohort, and 0.767 (0.613-0.921) in validation cohort, which were extremely higher than the other biomarkers. The patients with FPR-SII combined score 2 harbored worse prognosis compared to the combined score 0 in discovery (p Conclusions: High-grade cancer elicited inflammation could attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC. FPR-SII combined score was the best inflammatory biomarker to monitor and predict the progression of advanced NSCLC patients with treatment of TKI. (Copyright © 2021 Elsevier Ltd. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Biomarkers; Chronic inflammation; EGFR-TKI; NSCLC |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Biomarkers, Tumor) 0 (Protein Kinase Inhibitors) EC 2.7.10.1 (EGFR protein, human) EC 2.7.10.1 (ErbB Receptors) |
| تواريخ الأحداث: | Date Created: 20210622 Date Completed: 20220209 Latest Revision: 20220209 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.phrs.2021.105734 |
| PMID: | 34157424 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-1186 |
|---|---|
| DOI: | 10.1016/j.phrs.2021.105734 |